Precigen, Inc. · NASDAQ:PGEN
Precigen — Q4 2019 Earnings Presentation
12 slides from Precigen's earnings presentation, Mar 2, 2020
Slide 1: Precigen 4Q-2019 Business Update
Precigen 4Q-2019 Business Update 2 March 2020 Exhibit 99.2
Slide 2: Forward-looking Statements
Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Precigen's current expectations and projecti
Slide 3: Precigen: Setting the Stage for Success
Precigen: Setting the Stage for Success Ziopharm licensing agreement Merck KGaA agreement PRGN-3006 IND clearance PRGN-3005 IND clearance Intrexon Health formed Manufacturing facility opened First patient dosed for PRGN-3006 First patient dosed for PRGN-3005 Announced completion of dosing of first c
Slide 4: Adhering to Operating Principles to Deliver Value to All Stakeholders
Adhering to Operating Principles to Deliver Value to All Stakeholders PRECIGEN’S VISION FOR PATIENTS Develop life-saving and cost-conscious therapies utilizing our cutting-edge platform technologies for patients with unmet need FISCAL STRENGTH Responsible capital allocation to ensure runway for maxi
Slide 5: Our Non-Healthcare Asset Strategy
Our Non-Healthcare Asset Strategy MBP Titan Significantly reduce cash requirement Increase operational efficiencies Support partnering discussions Trans Ova Genetics Continue to evaluate strategic alternatives Increase operational efficiencies Contribute cash to Precigen
Slide 6: One Precigen: Deploying Novel Approaches to Address Unmet Healthcare Needs
One Precigen: Deploying Novel Approaches to Address Unmet Healthcare Needs Therapeutic gene(s) inserted Non-viral multi-gene delivery Non-exhausted, stem-like T cell phenotype Higher antigen-specific expansion Enhanced in vivo persistence Ability to deplete with kill switch Overnight manufacturing p
Slide 7: Robust Pipeline with Many Milestones to Drive Value
PRODUCT PLATFORM INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 STATUS / MILESTONES PARTNER PRECIGEN AG019 ActoBiotics Type 1 Diabetes Interim data in 3Q20 PRGN-3005 UltraCAR-T Ovarian Cancer Initial data in 2H20 PRGN-3006 UltraCAR-T AML, MDS Initial data in 2H20 INXN-4001 Non-viral UltraV
Slide 8: Our UltraCAR-T Platform Promises a More Effective Way to Treat Patients
Our UltraCAR-T™ Platform Promises a More Effective Way to Treat Patients Reliance on viral vectors Complexity of manufacturing viral vectors Long and complex CAR-T cell manufacturing process Long delays for patients High cost of manufacturing Exhausted T cell phenotype Major challenges in solid tumo
Slide 9: PRGN-3005, a first-in-class therapy in ovarian cancer
PRGN-3005, a first-in-class therapy in ovarian cancer Phase 1 trial is ongoing Arm A: Intraperitoneal (IP) infusion; Arm B: Intravenous (IV) infusion Second cohort for IP arm currently enrolling patients 100% manufacturing success to date Encouraging preliminary findings of UltraCAR-T kinetics Initi
Slide 10: PRGN-3006, a first-in-class therapy in AML
PRGN-3006, a first-in-class therapy in AML Phase 1/1b trial is ongoing Arm 1: No Lymphodepletion ; Arm 2: With Lymphodepletion Second cohort for Arm 1 and First cohort for Arm 2 currently enrolling 100% manufacturing success to date Encouraging preliminary findings of UltraCAR-T kinetics Initial dat
Slide 11: Multiple Milestones to Drive Value in 2020 and Beyond
Multiple Milestones to Drive Value in 2020 and Beyond Initial data from IP arm of PRGN-3005 UltraCAR-T™ Phase 1 trial in Ovarian Cancer Initial data from PRGN-3006 UltraCAR-T™ Phase 1 trial in AML and MDS Interim data from Phase 2 trial of AG013 in Oral Mucositis Interim data from Phase 1b/2a trial
Slide 12: Precigen: Advancing Medicine with Precision
G PRECIGEN ADVANCING MEDICINE WITH PRECISION™ We Ga my